vTv Therapeutics (NASDAQ:VTVT) Announces Quarterly Earnings Results, Beats Estimates By $0.32 EPS

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.32, Zacks reports. The company had revenue of $0.02 million for the quarter.

vTv Therapeutics Price Performance

NASDAQ:VTVT opened at $17.60 on Friday. The firm has a market capitalization of $56.14 million, a price-to-earnings ratio of -3.89 and a beta of 1.07. The business has a 50 day simple moving average of $16.92 and a 200-day simple moving average of $15.44. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $30.99.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Alliance Global Partners assumed coverage on vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company. StockNews.com started coverage on vTv Therapeutics in a research report on Wednesday. They set a “sell” rating for the company.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.